1. Long-Term Visual Outcome in Inferior Posterior Staphyloma and Efficacy of Treatment for Complicated Choroidal Neovascularization
- Author
-
Ayako Takahashi, Sotaro Ooto, Hiroshi Tamura, Masahiro Miyake, Akihito Uji, Naoko Ueda-Arakawa, Manabu Miyata, Tomotaka Wakazono, Akitaka Tsujikawa, Kenji Yamashiro, Yuki Muraoka, and Ayaka Doi
- Subjects
medicine.medical_specialty ,Visual acuity ,genetic structures ,Clinical cohort ,Visual Acuity ,Angiogenesis Inhibitors ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Ranibizumab ,Ophthalmology ,Humans ,Medicine ,Treatment effect ,Prospective Studies ,Fluorescein Angiography ,030304 developmental biology ,0303 health sciences ,business.industry ,Choroidal Neovascularization ,eye diseases ,Treatment Outcome ,Choroidal neovascularization ,Intravitreal Injections ,030221 ophthalmology & optometry ,Posterior staphyloma ,sense organs ,medicine.symptom ,business ,Retinal exudate - Abstract
Purpose To investigate long-term visual outcome in inferior posterior staphyloma (IPS) in each group classified based on macular complications and to examine the treatment effect for eyes with IPS with choroidal neovascularization (CNV). Design Prospective clinical cohort study. Participants We analyzed 56 eyes of 43 consecutive patients with IPS who were followed for 4 years. Methods We classified eligible eyes into 3 groups based on baseline findings: eyes without CNV or retinal exudate (no-exudate group), eyes without CNV and with retinal exudate (exudate group), and eyes with CNV (CNV group). We investigated the best-corrected visual acuity (BCVA) and associated parameters for 4 years. Results BCVA declined during 4 years only in the exudate group (P = .002), whereas it was maintained for 4 years in the no-exudate and CNV groups (P = .53 and .20, respectively). Baseline BCVA was lower in the CNV group than in the exudate group (P = .004); however, the 4-year BCVA was not (P = .84). The 4-year BCVA was associated with baseline BCVA in all groups. Eyes in the CNV group required 9.0 ± 8.7 anti–vascular endothelial growth factor therapy in 4 years. Conclusions Better baseline BCVA in eyes with exudative IPS without CNV spontaneously declined in 4 years, whereas worse baseline BCVA in eyes with IPS with CNV did not, probably because of treatment for retinal exudate from CNV. Anti–vascular endothelial growth factor therapy would be effective for long-term maintenance of BCVA in eyes with IPS with CNV, similar to other diseases with CNV.
- Published
- 2021
- Full Text
- View/download PDF